Overview

Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

Status:
Active, not recruiting

Trial end date:
2021-11-04

Target enrollment:

Participant gender:

Summary

This investigator driven Phase Ib study will examine the safety, efficacy and biological effects of two schedules of pembrolizumab, an antibody targeted against anti-programmed cell death 1 (PD-1), which will be given either before or after stereotactic ablative body radiotherapy (SABR) for metastatic NSCLC.

Phase:

Phase 1

Details

Lead Sponsor:

Peter MacCallum Cancer Centre, Australia

Treatments:

Pembrolizumab